

Contents

Contributors	xiii	2.4.2 Processing of CRISPR array	19
About the editors	xv	2.4.3 CRISPR-interference	19
Foreword	xvii	2.5 Application of CRISPR/Cas9 systems	20
Preface	xix	2.6 Conclusions	21
Acknowledgments	xxi	References	21
1. An introduction to genome editing CRISPR-Cas systems		3. Exploring the potential of CRISPR-Cas9 for the removal of human viruses	
<i>Vijai Singh</i>		<i>Happy Panchasara, Shreya Patel and Vijai Singh</i>	
1.1 Introduction	1	3.1 Introduction	27
1.2 History and classification of CRISPR-Cas systems	1	3.2 CRISPR-Cas9 system as an antiviral agent	27
1.3 Milestones in the CRISPR-Cas systems	3	3.2.1 Human immunodeficiency virus	28
1.4 Development of CRISPR-CAS9 system for genome editing	4	3.2.2 Hepatitis B virus	31
1.4.1 Microbial genome editing using CRISPR-Cas9 system	4	3.2.3 Epstein-Barr virus	31
1.4.2 Viral genome editing using CRISPR-Cas9 system	5	3.2.4 Herpes simplex virus	32
1.4.3 Mammalian cells genome editing using CRISPR-Cas9 system for therapeutic applications	6	3.2.5 Human papillomavirus	32
1.5 Recent developments in CRISPR interference platform	7	3.3 CRISPR delivery in mammalian cells	33
1.5.1 CRISPRi	7	3.4 Challenges to the use of CRISPR-CAS9 as therapy	34
1.5.2 CRISPRa	8	3.5 Conclusion and future perspective	35
1.5.3 Loci imaging	8	References	35
1.6 Conclusion and future remarks	8		
References	9	4. Programmable removal of bacterial pathogens using CRISPR-Cas9 system	
2. Evolution and molecular mechanism of CRISPR/Cas9 systems		<i>Gargi Bhattacharjee, Khushal Khambhati, Nisarg Gohil and Vijai Singh</i>	
<i>Kul Bhushan</i>		4.1 Introduction	39
2.1 Introduction	15	4.2 Mechanism of CRISPR-Cas systems	40
2.2 Evolution of CRISPR/Cas9 systems	15	4.3 Application of CRISPR-Cas9 system as an antimicrobial agent	40
2.3 Classification of CRISPR/Cas systems	16	4.3.1 CRISPR-Cas9 for removal of mammalian pathogenic bacteria	40
2.3.1 Class 1 systems	17	4.3.2 CRISPR-Cas9 for removal of plant pathogenic bacteria	41
2.3.2 Class 2 systems	17	4.4 Bacteriophage engineering to extend the host range	42
2.4 Molecular mechanism of CRISPR/Cas-mediated defense systems	17	4.5 Conclusion and future remarks	42
2.4.1 Acquisition of new spacer	18	Acknowledgment	43
		References	43

5. Targeted genome editing using CRISPR/Cas9 system in fungi

Takayuki Arazoe and Osamu Mizutani

5.1	Introduction	45
5.2	Genome editing in yeasts	46
5.2.1	Genome editing in <i>S. Cerevisiae</i>	47
5.2.2	Genome editing in non-conventional yeasts	53
5.2.3	Conclusion, challenges, and future remarks	55
5.3	Genome editing in filamentous fungi	56
5.3.1	Genome editing in filamentous fungi in 2015	56
5.3.2	Genome editing in filamentous fungi after 2016	59
5.3.3	Large deletion of some filamentous fungi in genome editing via NHEJ repair	61
5.3.4	Conclusion and future remarks	62
	References	63

6. CRISPR-Cas9 system for fungi genome engineering toward industrial applications

Lakkakula Satish, Sasanala Shamili, Balasubramanian C. Muthubharathi, Stanislaus Antony Ceasar, Ariel Kushmaro, Vijai Singh and Yaron Sitrit

6.1	Introduction	69
6.2	Challenges in editing fungal genome	69
6.3	Industrial applications of CRISPR-Cas9 methods in fungi genome editing	72
6.4	Implementations of the CRISPR-Cas9 in fungi	72
6.5	CRISPR-based gene regulation in fungi	77
6.6	CRISPR-Cas9 a novel approach for biological control	77
6.7	Further developments required for fungi genome editing	78
6.8	Conclusion and future prospects	78
	Acknowledgment	78
	References	78

7. Development and challenges of using CRISPR-Cas9 system in mammals

Khushal Khambhati, Nisarg Gohil, Gargi Bhattacharjee and Vijai Singh

7.1	Introduction	83
7.2	Principle mechanism behind CRISPR-Cas9 mediated gene editing	83

7.3	Delivery of CRISPR-Cas9 component	84
7.4	Recent development and applications of CRISPR-Cas9 for human and mammalian diseases	84

7.4.1	Cancer	85
7.4.2	Cataract	85
7.4.3	Duchenne muscular dystrophy	86
7.4.4	Tyrosinemia type-1	86
7.4.5	Cystic fibrosis	87
7.4.6	Urea cycle disorder	87
7.4.7	Blood disorder	88
7.4.8	Retinal degenerative	88
7.4.9	Cardiovascular disease	89
7.4.10	Amyotrophic lateral sclerosis	89
7.4.11	Huntington's disease	89

7.5	Key issues and challenges	89
7.6	Conclusions and future remarks	90
	Acknowledgment	90
	References	90

8. CRISPR-Cas9 system "a mighty player in cancer therapy"

Siddharth Manvati and Pawan K. Dhar

8.1	Introduction	95
8.2	Functional characterization of cancer-related genes by conventional methods	95
8.3	Involvements of the non-coding region of the human genome in a certain type of cancers could give a novel therapeutic targets	95
8.3.1	Long non-coding RNA (lncRNAs) functional drivers of breast cancer progression and invagination	96
8.4	Challenges and advancement needed in CRISPR-Cas9 method for cancer treatments	96
8.5	CRISPR-Cas9 and the future of cancer therapy	97
	References	98

9. CRISPR-Cas9 for therapy: the challenges and ways to overcome them

Sundaram Acharya, Souvik Maiti and Debojyoti Chakraborty

9.1	Introduction	101
9.2	CRISPR-Cas9 as a drug	102
9.3	A match made in heaven; iPSC and CRISPR-Cas9	104
9.4	Ex-vivo versus in-vivo editing	106
9.5	Bench-to-bedside challenges	107
9.6	Conclusion	107
	References	108

10. Engineering of Cas9 for improved functionality

Dhvani Sandip Vora, Jaspreet Kaur Dhanjal and Durai Sundar

10.1	Introduction	111
10.2	Cas9 variants with altered nuclease activity	112
10.2.1	nCas9	112
10.2.2	Dead Cas9 (dCas9)	112
10.3	Cas9 variants with improved PAM specificity	112
10.4	Switchable Cas9	113
10.4.1	Reconstitution of Cas9 via sgRNA	113
10.4.2	Ligand-dependent re-assembly of Cas9	113
10.4.3	Photo-inducible reconstitution of Cas9	115
10.4.4	Intein-inducible recombining of Cas9	115
10.5	Inducible Cas9	116
10.6	gRNA editing	118
10.7	Other CRISPR-associated endonucleases	119
	References	119

11. The current progress of CRISPR/Cas9 development in plants

Purva Bhalothia, Kalpesh Yajnik, Anshu Alok and Santosh Kumar Upadhyay

11.1	Introduction	123
11.2	Mechanism of Crispr/Cas9	123
11.3	Multiplex Crispr/Cas9	125
11.4	Metabolic engineering in plants using Crispr/Cas9	125
11.5	Crispr/Cas9 mediated live cell imaging	126
11.6	Non-transgenic plants through CRISPR/Cas9	126
11.7	Conclusions and future remarks	127
	Acknowledgments	128
	References	128

12. Fruit crops improvement using CRISPR/Cas9 system

Navneet Kaur, Praveen Awasthi and Siddharth Tiwari

12.1	Introduction	131
12.2	Nutritional aspects of fruit crops	132
12.3	Genome editing as a tool towards fruit crop improvement	134

12.3.1	CRISPR/Cas9 technology toward nutritional enrichment of fruit crop	134
12.4	Crispr/Cas9 system: a tool for improving stress tolerance in fruit crops	138
12.4.1	Abiotic stress	138
12.4.2	Biotic stress	139
12.5	Challenges pertaining to fruit crop improvement via Crispr/Cas9 technology	139
12.5.1	Genome completeness and off-target effects	139
12.5.2	Tissue culture and CRISPR/Cas9 delivery methods	140
12.5.3	Challenges in CRISPR/Cas9 mediated knock-in approach	140
12.6	Conclusion and future perspective	140
	Acknowledgments	141
	References	141

13. CRISPR/Cas9 engineered viral immunity in plants

Dharmendra Pratap and Ankit Kumar

13.1	Introduction	147
13.2	Plant viruses and existing virus control strategies	147
13.3	Gene editing with CRISPR-Cas system	148
13.4	CRISPR-Cas-mediated viral resistance through PDR approach	149
13.5	CRISPR-Cas mediated viral resistance by interfering host encoded genes	152
13.6	Conclusion and future perspectives	152
	References	153

14. Genome engineering in medicinally important plants using CRISPR/Cas9 tool

Anshu Alok, Prateek Jain, Jitesh Kumar, Kalpesh Yajnik and Purva Bhalothia

14.1	Introduction	155
14.2	Designing of gRNA and vectors construction	156
14.3	CRISPR-Cas9 construct delivery methods into plant cells	156
14.3.1	Agro-infiltration into leaf	156
14.3.2	<i>A. rhizogenes</i> -mediated transformation	156
14.3.3	Biolistic transformation facilitate for DNA free editing	157

14.3.4	PEG mediated delivery of CRISPR-Cas9 ribonucleoprotein complexes	158
14.4	Pathway engineering using CRISPR-Cas9	158
14.5	Editing in hairy roots of medicinal plants for producing secondary metabolites	158
14.6	Future perspective of genome editing in medicinal plants	159
	References	160

15. Genome editing of algal species by CRISPR Cas9 for biofuels

Amita Tanwar and Shashi Kumar

15.1	Introduction	163
15.2	Genetic engineering of algae	164
15.2.1	Methods of DNA delivery	164
15.2.2	Selectable marker	164
15.2.3	Merits and demerits of nuclear and chloroplast transformation	165
15.3	CRISPR	165
15.3.1	Brief introduction to CRISPR-Cas9	165
15.3.2	Mechanism of CRISPR-Cas9 guided cleavage	165
15.3.3	Cas9 variants	167
15.3.4	Modes of Cas9 expression into the algal systems	167
15.4	CRISPR over random mutagenesis and RNAi	167
15.5	Target pathways for development of microalgae as biofuel feedstocks	168
15.6	CRISPR-Cas9 in microalgae	168
15.6.1	Genome editing in <i>C. reinhardtii</i> using Cas9 nuclease	168
15.6.2	Demonstration of Cas9 suitability in diatom species by targeting genes with visible or auxotrophic phenotypes	169
15.6.3	CRISPR/Cas9 as a tool of choice for editing in the industrial microalgae	169
15.6.4	Use of Cpf1 and other Cas9 homologs in algae for DNA integration	170
15.6.5	Episomes for DNA editing	170
15.6.6	Biolytic delivery of RNPs to generate auxotrophic mutants in diatom	171
15.7	CRISPR workflow in microalgae	171
15.7.1	Selection of target gene(s)	171

15.7.2	Choice of Cas9 expression system	171
15.7.3	sgRNA design	171
15.7.4	Transformation of cells with Cas9	171
15.7.5	Screening of mutants for editing	171
15.7.6	Characterization of mutants	171
15.8	Conclusion, challenges and future remarks	172
	References	173

16. Development and use of CRISPR in industrial applications

Ali Samy Abdelaal and Syed Shams Yazdani

16.1	Historical perspectives	177
16.1.1	Genome editing strategies	177
16.1.2	Discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)	177
16.1.3	Mechanism of action of CRISPR-Cas immune systems	177
16.1.4	The rise of CRISPR	178
16.2	Development of CRISPR based technologies	179
16.3	Design tools for CRISPR-Cas9 based genome editing	180
16.4	Industrial products developed using CRISPR	180
16.4.1	Biofuels	185
16.4.2	Organic acids	189
16.4.3	Phytochemicals	189
16.4.4	Polyhydroxyalkanoates (PHA)	190
16.4.5	Amino acids	190
16.4.6	Health care	191
16.4.7	Engineering sugar metabolism for improved feedstock utilization	191
16.5	Conclusion	191
	References	191

17. Functional understanding of CRISPR interference: its advantages and limitations for gene silencing in bacteria

Ajitesh Lunge, Eira Choudhary, Rishabh Sharma, Radhika Gupta and Nisheeth Agarwal

17.1	Introduction	199
17.1.1	Need of genome editing in bacteria: annotating the unknowns	199

17.1.2	CRISPR-Cas system: the foremost choice of genome editing in the 21st century	199			
17.1.3	Type II CRISPR-Cas system: a role model for CRISPR-interference	201			
17.2	Gene silencing by CRISPRi in bacteria	203			
17.2.1	The concept of CRISPRi	203			
17.2.2	Critical components of CRISPRi	204			
17.2.3	Understanding the functional complex formation	207			
17.2.4	Knocking down the gene expression by CRISPRi in bacteria	209			
17.3	Advantages and limitations of CRISPRi in bacteria	210			
17.3.1	Advantages of CRISPRi	211			
17.3.2	Limitations of CRISPRi	214			
17.4	Concluding remarks	214			
	Acknowledgments	215			
	References	215			
18.	Genome engineering in insects: focus on the CRISPR/Cas9 system				
	<i>V. Edwin Hillary, Stanislaus Antony Ceasar and S. Ignacimuthu</i>				
18.1	Introduction	219			
18.2	Tools used for genome engineering	220			
18.2.1	ZFN	220			
18.2.2	TALEN	221			
18.2.3	CRISPR/Cas9	222			
18.3	Genome engineering in insects using CRISPR/Cas9	226			
18.3.1	Fruit fly (<i>D. melanogaster</i>)	228			
18.3.2	Mosquitoes	228			
18.3.3	Silkworm (<i>B. mori</i>)	235			
18.3.4	Butterflies	236			
18.4	Targeting efficiency and off-target effects of CRISPR/Cas9	237			
18.5	Genome engineering in insects using ZFN	237			
18.6	Genome engineering in insects using TALEN	239			
18.7	Gene drive	239			
18.7.1	History of gene drive systems	239			
18.7.2	Mechanism of CRISPR/Cas9 gene drive	239			
18.8	Ethical concerns of genome editing	241			
18.9	Conclusion	241			
	Acknowledgments	241			
	References	241			
19.	Recent progress of CRISPR-Cas9 in zebra fish				
	<i>Dharmendra Kumar Chaudhary, Sandeep Kumar Singh, Nisarg Gohil and Gargi Bhattacharjee</i>				
19.1	Introduction	251			
19.2	Methods of genome editing	251			
19.2.1	Zinc finger proteins (ZFNs)	251			
19.2.2	Transcription activator-like effector nucleases (TALEN)	252			
19.2.3	CRISPR-Cas9 for genome editing	252			
19.3	CRISPR-Cas9 system for genome editing of zebra fish	253			
19.4	Applications of CRISPR-Cas9 in zebrafish	253			
19.4.1	Use of CRISPR-Cas9 system in developmental biology	253			
19.4.2	Use of CRISPR-Cas9 system in neuronal development	256			
19.4.3	Gene therapy	257			
19.4.4	Cardiomyopathies	257			
19.5	Conclusion and future remarks	258			
	References	258			
20.	CRISPR: a revolutionary tool for genome engineering in the protozoan parasites				
	<i>Manish Sharma and Abhisheka Bansal</i>				
20.1	Introduction	263			
20.2	Limitations in genome engineering of apicomplexan parasites	265			
20.3	Gene editing tools for studying protozoan parasites	266			
20.3.1	CRISPR/Cas9 for Plasmodium gene editing	266			
20.3.2	CRISPR/Cas9 for <i>T. gondii</i> gene editing	275			
20.3.3	CRISPR/Cas9 for <i>C. parvum</i> gene editing	277			
20.4	Concluding remarks	278			
	Acknowledgments	278			
	References	278			
21.	Emergent challenges for CRISPR: biosafety, biosecurity, patenting, and regulatory issues				
	<i>Darren Braddick and Rina Fanny Ramarohetra</i>				
	Abbreviations	281			
21.1	Introduction	281			

21.2	Biosafety	283	21.4.2	Foundational patent dispute	291
21.2.1	Cancer risks through TP53/ p53 dysfunction	283	21.4.3	The patenting of CRISPR products	292
21.2.2	Off-target effects	283	21.4.4	Patentability of CRISPR products	293
21.2.3	Genomic rearrangements and mosaicism	284	21.5	Regulatory issues with CRISPR products	294
21.2.4	Human germ-line and embryo modification	285	21.5.1	The global regulatory land- scape of CRISPR	294
21.2.5	Delivery of CRISPR products	285	21.5.2	Human gene editing	295
21.2.6	Availability of CRISPR and DIY use	286	21.5.3	CRISPR in agricultural projects	295
21.3	Biosecurity	286	21.5.4	Regulations around dual use and the sale of essential parts	296
21.3.1	The publicized severity of potential biosecurity threats	287	21.5.5	Regulation through patents	297
21.3.2	Realizing potential bio- security threats	287	21.6	Conclusions and future remarks	298
21.3.3	Gene drives and ecological disruption	288	References		300
21.3.4	Dual use technologies	288	Appendices		309
21.3.5	Biological countermeasures against biosecurity risks	289	Glossary		313
21.4	Patenting CRISPR technologies and products	291	Author Index		315
21.4.1	Obviousness in CRISPR patenting	291	Subject Index		349